- Home
- A-Z Publications
- Recent Patents on Anti-Cancer Drug Discovery
- Previous Issues
- Volume 19, Issue 5, 2024
Recent Patents on Anti-Cancer Drug Discovery - Volume 19, Issue 5, 2024
Volume 19, Issue 5, 2024
-
-
Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies
Authors: Yangjie Liu, Cao Peng, Faiza Ahad, Syed A. Ali Zaidi, Tobias Achu Muluh and Qiuxia FuChimeric antigen receptor T-cells, known as CAR-T cells, represent a promising breakthrough in the realm of adoptive cell therapy. These T-cells are genetically engineered to carry chimeric antigen receptors that specifically target tumors. They have achieved notable success in the treatment of blood-related cancers, breathing new life into this field of medical research. However, numerous obstacles limit chimeric antigen recept Read More
-
-
-
Research Progress on the Anticancer Activity of Plant Polysaccharides
Authors: Qiaoyan Liu, Bo Song, Sen Tong, Qiuqiong Yang, Huanhuan Zhao, Jia Guo, Xuexia Tian, Renjie Chang and Junzi WuTumor is a serious threat to human health, with extremely high morbidity and mortality rates. However, tumor treatment is challenging, and the development of antitumor drugs has always been a significant research focus. Plant polysaccharides are known to possess various biological activities. They have many pharmacological properties such as immunomodulation, antitumor, antiviral, antioxidative, antithrombotic, a Read More
-
-
-
The Clinical Significance and Prognostic Value of ALDH1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
Authors: Dong Li, Yu Cao, Cheng-Wen Luo, Li-ping Zhang and Ying-Bo ZouBackground: The results of the association between aldehyde dehydrogenase 1 (ALDH1) expression and prognosis of non-small cell lung cancer (NSCLC) are contradictory. We conducted this meta-analysis to investigate the clinical significance and prognostic value of ALDH1 in NSCLC. Methods: The databases PubMed, Web of Science, EMBASE, the Cochrane Library, Wanfang, and CNKI were systematically queried to id Read More
-
-
-
TGF-β Score based on Silico Analysis can Robustly Predict Prognosis and Immunological Characteristics in Lower-grade Glioma: The Evidence from Multicenter Studies
Authors: Weizhong Zhang, Zhiyuan Yan, Feng Zhao, Qinggui He and Hongbo XuIntroduction: Nowadays, mounting evidence shows that variations in TGF-β signaling pathway-related components influence tumor development. Current research has patents describing the use of anti-TGF-β antibodies and checkpoint inhibitors for the treatment of proliferative diseases. Importantly, TGF-β signaling pathway is significant for lower-grade glioma (LGG) to evade host immunity. Loss of particular tumor antige Read More
-
-
-
CK2B is a Prognostic Biomarker and a Potential Drug Target for Hepatocellular Carcinoma
Authors: Huiru Dai, Minling Liu, Yuxi Pan, Tingwei Li, Yihang Pan, Zhe-Sheng Chen, Jing Li, Yuchen Liu and Shuo FangBackground: Although casein kinase II subunit beta (CK2B) was previously reported to be involved in human cancers, such as hepatocellular carcinoma (HCC), there has been no systematic assessment of CK2B in HCC. Objective: To assess the potential function of CK2B as a prognostic biomarker and possible druggable target in HCC. Methods: The Cancer Genome Atlas database was accessed to investigate the potentia Read More
-
-
-
Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening
Authors: Wei Duan, Yu Chen, Jinlu Shan and Qian LiBackground: Osteosarcoma (OS) is a common primary malignant bone tumor that mainly occurs in children and adolescents. The use of IL-8 inhibitor compounds has been reported in patents, which can be used to treat and/or prevent osteosarcoma, but the pathogenesis of osteosarcoma remains to be investigated. At present, osteoblasts and osteoclasts play an important role in the occurrence and development of OS. Ho Read More
-
-
-
Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma
Authors: Wei Wang and Shengwei LiBackground: Lung cancer is the most prevalent malignancy worldwide, and lung adenocarcinoma (LUAD) accounts for a substantial proportion of all cases. N6-methyladenosine (m6A) is the most frequent post-transcriptional modification in mRNAs that also plays a role in cancer development. Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) is a reader of m6A modification, which can affect tumor invasion, migrati Read More
-
-
-
Fatty Acid Metabolism Signature Contributes to the Molecular Diagnosis of a Malignant Gastric Cancer Subtype with Poor Prognosis and Lower Mutation Burden
Authors: Zhengwei Chen and Guoxiong ChengBackground: Gastric cancer (GC) is a common gastrointestinal tumor with high morbidity and mortality. Fatty acid metabolism (FAM) contributes to GC development. Patents have been issued for the use of compositions comprising fatty acid analogues for the treatment of many clinical conditions. However, its clinical significance and its relationship with tumor-related mutations have not been thoroughly discovered. This Read More
-
-
-
Integrating Bioinformatics and Drug Sensitivity Analyses to Identify Molecular Characteristics Associated with Targeting Necroptosis in Breast Cancer and their Clinical Prognostic Significance
Authors: Chang Zheng, Hanbin Guo, Yongpan Mo and Guowen LiuBackground: Breast cancer accounts for over 1.8 million new cases worldwide annually, and prompt diagnosis and treatment are imperative to prevent mortality. Necroptosis, a form of programmed cell death, is thought to be a critical pathway for cancer cell apoptosis, yet, its relationship with breast cancer progression and molecular mechanisms remains largely unexplored. Objectives: Our study aims to investigate the m Read More
-
-
-
Identification of the Roles of Coagulation-related Signature and its Key Factor RABIF in Hepatoma Cell Malignancy
Authors: Yanying Chen, Yin Li and Bingyi ZhouBackground: Hepatoma is a high morbidity and mortality cancer, and coagulation is a potential oncogenic mechanism for hepatoma development. Objective: In this study, we aimed to reveal the role of coagulation in hepatoma. Methods: We applied the LASSO to construct a coagulation-related risk score (CRS) and a clinical nomogram with independent validation. The heterogeneity of various aspects, including functional enrich Read More
-
Volumes & issues
-
Volume 20 (2025)
-
Volume 19 (2024)
-
Volume 18 (2023)
-
Volume 17 (2022)
-
Volume 16 (2021)
-
Volume 15 (2020)
-
Volume 14 (2019)
-
Volume 13 (2018)
-
Volume 12 (2017)
-
Volume 11 (2016)
-
Volume 10 (2015)
-
Volume 9 (2014)
-
Volume 8 (2013)
-
Volume 7 (2012)
-
Volume 6 (2011)
-
Volume 5 (2010)
-
Volume 4 (2009)
-
Volume 3 (2008)
-
Volume 2 (2007)
-
Volume 1 (2006)
Most Read This Month
Article
content/journals/pra
Journal
10
5
false
en
